Literature DB >> 3257886

Human eosinophil hematopoiesis studied in vitro by means of murine eosinophil differentiation factor (IL5): production of functionally active eosinophils from normal human bone marrow.

E J Clutterbuck1, C J Sanderson.   

Abstract

The production of human eosinophils in vitro from normal bone marrow by using murine eosinophil differentiation factor (mEDF/interleukin 5) is described. Eosinophil production was selective and first detectable after 14 days and reached a peak between 21 and 35 days when they were the predominant cell type (41% to 89%). Until day 14, all the eosinophils were typical myelocytes, developing thereafter into metamyelocytes and mature cells. All cell types had characteristic light- and electron-microscopic features, apart from the absence of granules with crystalline cores. The eosinophils produced were readily recovered, and both immature myelocytes and mature cells were functionally active in an antibody-dependent, cell-mediated cytotoxicity assay. mEDF added into the assay enhanced the cytotoxicity but to a lower degree than previously reported for peripheral blood eosinophils, which suggests that they may be partially activated. The possibility that eosinophils could be deactivated was tested by removing mEDF from the culture medium. The eosinophils retained viability and functional activity, however, and showed no increased ability to be activated by mEDF for up to six days after removing the mEDF. The liquid culture of human bone marrow was shown to be an alternative assay for eosinophil differentiation factors to colony formation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257886

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Haemopoietic growth factors: their role in cell development and their clinical use.

Authors:  N G Testa; T M Dexter
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

2.  The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice.

Authors:  M Korenaga; Y Hitoshi; N Yamaguchi; Y Sato; K Takatsu; I Tada
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

3.  Effect of murine recombinant interleukin-5 on the cell population in guinea-pig airways.

Authors:  T Iwama; H Nagai; H Suda; N Tsuruoka; A Koda
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

4.  Selective gamma-chain T-cell receptor gene rearrangements in a patient with Omenn's syndrome: absence of V-II subgroup (V gamma 9) transcripts.

Authors:  G Mathioudakis; R A Good; Y Chernajovsky; N K Day; C D Platsoucas
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

Review 5.  Eosinophils and disease pathogenesis.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

6.  Tryptophan-induced eosinophilia-myalgia syndrome.

Authors:  L A Criswell; K E Sack
Journal:  West J Med       Date:  1990-09

Review 7.  Cytokine-induced human basophil/mast cell growth and differentiation in vitro.

Authors:  J A Denburg
Journal:  Springer Semin Immunopathol       Date:  1990

8.  Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia.

Authors:  J Wang; K Palmer; J Lŏtvall; S Milan; X F Lei; K I Matthaei; J Gauldie; M D Inman; M Jordana; Z Xing
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

9.  Preparation and characterization of human interleukin-5 expressed in recombinant Escherichia coli.

Authors:  A E Proudfoot; D Fattah; E H Kawashima; A Bernard; P T Wingfield
Journal:  Biochem J       Date:  1990-09-01       Impact factor: 3.857

Review 10.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.